

**ADURS2019 Speakers
Titles/Objectives**

Thursday, February 21, 2019

John Coster, PhD, RPh, Director, Division of Pharmacy; Center for Medicaid & CHIP Services; Centers for Medicare & Medicaid Services (Invited)

Title: CMS Update

No CE Hours

Friday, February 22, 2019

Jason Beaman, DO, MS, MPH, FAPA, Chair, Dept. of Psychiatry and Behavioral Sciences, OK State University

Title: Opioid Epidemic and Treatment

ACPE UAN: 0128-9999-19-007-L01-P

CPE: 1.0 contact hour / Knowledge-based activity

Objectives:

1. Describe the current status of the Opioid Epidemic in the United States.
2. Explain the Neurobiology of addiction.
3. Describe best evidence-based treatment for Opioid-Use Disorder.

Sarah Servid, PharmD, P&T Clinical Coordinator, Drug Use Research & Mgmt Program, Oregon State University

Title: Clinical Pearl: Benzodiazepine Days' Supply Limits in Oregon

ACPE UAN: 0128-9999-19-008-L04-P

CPE: 0.5 contact hour / Knowledge-based activity

Objectives:

1. State the rationale and purpose for benzodiazepine days' supply limits.
2. Describe how the benzodiazepine days' supply limits were implemented in Oregon.
3. Explain how patients can get benzodiazepines for durations beyond 4 weeks.
4. Identify challenges encountered with initial and ongoing implementation of the policy.

Carol Ott, PharmD, BCPP, Clinical Professor of Pharmacy Practice, Purdue University

Title: Use of a Fax Intervention to Decrease Antipsychotic Prescribing in Oppositional Defiant Disorder

ACPE UAN: 0128-9999-19-009-L01-P

CPE: 1.0 contact hour / Knowledge-based activity

Objectives:

1. Describe the current treatment evidence-base for oppositional defiant disorder (ODD) and comorbid attention-deficit hyperactivity disorder (ADHD)
2. Identify statistics and demographic information related to the use of antipsychotics in ODD.
3. Explain the effective use of a fax intervention to promote appropriate prescribing in ODD.

Donna Sullivan, PharmD, MS, Chief Pharmacy Officer, Washington Health Care Authority

Title: Managing High Cost Physician Administered Drugs in the Pharmacy Services Unit

ACPE UAN: 0128-9999-19-010-L04-P

CPE: 0.5 contact hour / Knowledge-based activity

Objectives:

1. Define Physician Administered Drugs.
2. Explain how to identify High Cost Drugs.
3. Describe how clinical criteria are developed for Physician Administered Drugs.
4. Explain how high cost physician administered drugs may be managed by pharmacists in the Pharmacy Services unit.

Charles Semling, PharmD, BS, RPh, Pharmacist, Alaska Medicaid

Title: Physician Administered Drugs – Medical Side

ACPE UAN: 0128-9999-19-011-L04-P

CPE: 0.5 contact hour / Knowledge-based activity

Objectives:

1. Define buy-and-bill as it relates to physician-administered drugs.
2. Cite the sources for various pharmaceutical pricing benchmarks and their respective application challenges with physician-administered medications.

3. Prepare a gap-analysis to improve the effectiveness of their physician-administered drug program.

Jacquelyn Hedlund, MD, MS, FACP, Associate Medical Director, Change Healthcare

Title: Big Breakthroughs in the Treatment of Hemophilia

ACPE UAN: 0128-9999-19-012-L01-P

CPE: 1.0 contact hours / Knowledge-based CPE activity

Objectives:

1. Explain the differences between Hemophilia A, B and acquired hemophilia and state the objectives of treatment.
2. Differentiate between the available treatments for the different types of hemophilia and be able to specify the benefits and limitations of various factor replacement products.
3. Describe factor inhibitors including the risks of developing inhibitors, goals of therapy and treatment options.
4. Discuss critically the costs associated with care, risks of non-compliance with therapy and recent changes in management of members with complicated bleeding histories.

Melissa Abbott, PharmD, Clinical Pharmacist, Pharmacy Management Consultants

Title: PEARL: Update on Cell and Gene Therapies

ACPE UAN: 0128-9999-19-013-L04-P

CPE: 0.5 contact hours / Knowledge-based CPE activity

Objectives:

1. Define gene therapy.
2. Identify specific examples of FDA-approved cell and gene therapies.
3. Describe barriers to reimbursement of cell and gene therapies in Medicaid.
4. List potential strategies to overcoming barriers for reimbursement of cell and gene therapies.

Bethany Holderread, PharmD, Clinical Coordinator, Pharmacy Management Consultants

Title: PEARL: Lessons Learned in Value-Based Arrangements

ACPE UAN: 0128-9999-19-014-L04-P

CPE: 0.5 contact hour / Knowledge-based CPE activity

Objectives:

1. List two barriers encountered by Oklahoma Medicaid when developing value-based payment arrangements
2. Identify claims-based outcome measures that can be used in a value-based payment arrangement
3. Define how a collaboration agreement differs from a value-based payment arrangement

Terry Cothran, PharmD, Director, Pharmacy Management Consultants

Title: State Roundtable - State Medicaid Programs (Part 1)

ACPE UAN: 0128-9999-19-015-L04-P

CPE: 1.25 contact hours / Knowledge-based CPE activity

Objectives:

1. Review retroDUR methodologies, processes, and outcomes of State Medicaid DUR initiatives.
2. Identify environmental factors that contribute to successes and failures of State Medicaid programs medication management initiatives.
3. Describe proposals for DUR initiatives based upon the proposal phase, implementation phase, program delivery and outcome evaluation phase.

Saturday, February 23, 2019

Thomas Frank, PharmD, BCPS, Frank Medical Consulting

Title: Things You May Have Missed While You Were in A Meeting: Ticks, Sneezes and Sugars

ACPE UAN: 0128-9999-19-016-L01-P

CPE: 1.0 contact hours / Knowledge-based CPE activity

Objectives:

1. Identify trends in therapeutics that have not received the attention they deserve based on their potential importance.
2. Review the connection between the Lone Star tick, red meat allergy, and the alpha-gal molecule.
3. Describe the advantages associated with sublingual immunotherapy that are behind the growth in this therapy.
4. Define the potential role of glycans in diagnosing and treating autoimmune conditions.

Patrick Medina, PharmD, BCOP, Professor of Medicine and Director of Pharmacy, College of Medicine, Stephenson Cancer Center.

Title: Recent Advances in Cancer Immunotherapy

ACPE UAN: 0128-9999-19-017-L01-P

CPE: 1.0 contact hours / Knowledge-based CPE activity

Objectives:

1. Differentiate the recently approved indications for cancer immunotherapies.
2. Explain the mechanism of action, efficacy, safety, and role of cancer immunotherapies for recent indications, as well as appropriate diagnostic testing.
3. Identify approaches for pharmacists to improve patient access to cancer immunotherapies, as well as provide appropriate supportive care.

Deborah Briggs, MD, FACNS, Director, Clinical Epilepsy Service, SBSI Comprehensive Epilepsy Program, Asst. Professor, UT Dell Medical School, Austin, TX

Title: Migraines, Not Just a Headache

ACPE UAN: 0128-9999-19-018-L01-P

CPE: 1.0 contact hours / Knowledge-based CPE activity

Objectives:

1. Review migraine pathogenesis to help discriminate between possible treatments.
2. Review current evidence on migraine prophylaxis to identify possible educational interventions.
3. Review current evidence on migraine abortive therapies to aid criteria development for Prior Authorizations or PDLs.

Maria M. Lowe, PharmD, BCPS, Health Data & Drug Information Clinical Specialist, *PatientsLikeMe*

Title: Pipeline Preview 2019

ACPE UAN: 0128-9999-19-019-L01-P

CPE: 1.5 contact hours / Knowledge-based CPE activity

Objectives:

1. Describe recent trends in the FDA approval process.
2. Review emerging pipeline agents with currently available therapeutic options.
3. List the expected generic availability of commonly used agents over the next two years.

Terry Cothran, PharmD, Director, Pharmacy Management Consultants

Title: State Roundtable - State Medicaid Programs (Part 2)

ACPE UAN: 0128-9999-19-020-L04-P

CPE: 1.25 contact hours / Knowledge based CPE activity

Objectives:

1. Review retroDUR methodologies, processes, and outcomes of State Medicaid DUR initiatives.
2. Identify environmental factors that contribute to successes and failures of State Medicaid programs medication management initiatives.
3. Describe proposals for DUR initiatives based upon the proposal phase, implementation phase, program delivery and outcome evaluation phase.



The **2019 ADURS Symposium** is designed for pharmacists specializing in medication utilization within State Medicaid programs and is sponsored by the American Drug Utilization Review Society (ADURS) and the Nebraska Council for Continuing Pharmacy Education (NCCPE). NCCPE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Credit for courses must be earned by the participant. Participants will earn **up to 12.5 contact hours** of continuing pharmacy education (CPE) credits for attendance of the entire symposium.

In order to earn CPE credits, the participant must complete an on-line educational evaluation form for each CPE session they attend within 15 days from the end of the symposium. The evaluation will collect birthdates (MMDD) and NABP e-Profile ID numbers (to receive CPE credits, the attendee must have an NABP e-Profile ID number). For more information about NABP e-Profile IDs, please see <http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service/>). ACPE CPE numbers and speaker objectives can be found in the program schedule. **CPE credits will be sent to your NABP e-Profile within 45 days of the program date.** For questions about CPE credits, please email Lorilyn Joyce at ljoyce.adurs@gmail.com.